RT Journal Article
T1 Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer.
A1 Gómez-Gómez, Enrique
A1 Carrasco-Valiente, Julia
A1 Campos-Hernández, Juan Pablo
A1 Blanca-Pedregosa, Ana Maria
A1 Jiménez-Vacas, Juan Manuel
A1 Ruiz-García, Jesus
A1 Valero-Rosa, Jose
A1 Luque, Raul Miguel
A1 Requena-Tapia, María José
K1 C-reactive protein
K1 inflammation
K1 metabolic syndrome
K1 significant prostate cancer
K1 testosterone
AB Recently, the influence that metabolic syndrome (MetS), hormonal alterations and inflammation might have on prostate cancer (PCa) risk has been a subject of controversial debate. Herein, we aimed to investigate the association between MetS-components, C-reactive protein (CRP) and testosterone levels, and the risk of clinically significant PCa (Sig-PCa) at the time of prostate biopsy. For that, men scheduled for transrectal ultrasound guided biopsy of the prostate were studied. Clinical, laboratory parameters and criteria for MetS characterization just before the biopsy were collected. A total of 524 patients were analysed, being 195 (37.2%) subsequently diagnosed with PCa and 240 (45.8%) meet the diagnostic criteria for MetS. Among patients with PCa, MetS-diagnosis was present in 94 (48.2%). Remarkably, a higher risk of Sig-PCa was associated to MetS, greater number of MetS-components and higher CRP levels (odds-ratio: 1.83, 1.30 and 2.00, respectively; P 2.5 mg/L with an increased Sig-PCa diagnosis and/or with aggressive features, suggesting that MetS and/or CRP levels might influence PCa pathophysiology.
YR 2018
FD 2018-11-18
LK http://hdl.handle.net/10668/13207
UL http://hdl.handle.net/10668/13207
LA en
DS RISalud
RD Apr 8, 2025